AI Article Synopsis
- Adoptive cell therapy using genetically modified T cells has shown success in treating blood cancers but faces challenges with solid tumors, prompting researchers to explore alternative immune cells for treatment.
- Macrophages, which can have both anti- and pro-tumor effects, are being studied for their potential in cancer therapy, leading to efforts in altering or depleting tumor-associated macrophages.
- The review discusses the role of macrophages in solid tumors, recent advancements in macrophage-based immunotherapies, and the development of chimeric antigen receptor macrophage cell therapy.
Article Abstract
Adoptive cell therapy with genetically modified T cells has generated exciting outcomes in hematologic malignancies, but its application to solid tumors has proven challenging. This gap has spurred the investigation of alternative immune cells as therapeutics. Macrophages are potent immune effector cells whose functional plasticity leads to antitumor as well as protumor function in different settings, and this plasticity has led to notable efforts to deplete or repolarize tumor-associated macrophages. Alternatively, macrophages could be adoptively transferred after genetic modification. In this review, we highlight the role of macrophages in solid tumors, the progress made with macrophage-focused immunotherapeutic modalities, and the emergence of chimeric antigen receptor macrophage cell therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/0008-5472.CAN-20-2990 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!